Developer docs
API playgroundTry for free, no card

Search company profiles

Glooko

Full company profile

uuid000039t

Namestring
Glooko
Legal namestring
Glooko, Inc.
Websiteurl
glooko.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Glooko is a Palo Alto-based digital health company that operates a cloud-based diabetes data management platform serving healthcare providers, hospitals, health systems, and people with diabetes. The platform aggregates data from more than 200 diabetes and health monitoring devices, integrates with major EHR systems including Epic, Oracle Health, and MEDITECH, and processes over 3 billion data points per month, enabling population health analytics, remote patient monitoring, and clinical decision support across the care continuum.

The product portfolio spans the outpatient Glooko Diabetes Management Platform and Glooko Web Application, a free consumer-facing Glooko Mobile App, the France-only Glooko XT remote patient monitoring product (reimbursed by the French National Health Insurance), and the inpatient EndoTool Glucose Management System acquired from Monarch Medical Technologies in September 2025. EndoTool, an FDA-cleared patient-specific insulin dosing platform using patented algorithms, was extended with the FDA 510(k)-cleared EndoTool IV Cloud in May 2026, the first FDA-cleared cloud-based insulin dosing platform for IV therapy in hospital settings. Glooko also operates a life sciences vertical supplying real-world device data and clinical research support to pharmaceutical partners including Eli Lilly, Novo Nordisk, and Sanofi.

The business model combines enterprise SaaS subscriptions to hospitals, health systems, and clinics (quote-based annual contracts) with a freemium consumer mobile app, supplemented by EndoTool inpatient software revenue and life sciences partnerships. The company sells through direct enterprise field sales, mobile app stores, and device manufacturer channel partnerships, and holds multiple top-tier security and medical device certifications (HITRUST r2, ISO 27001, SOC 2 Type II, HIPAA, GDPR, ISO 13485, EU MDR Class IIa, FDA 21 CFR Part 11). As of 2026, Glooko operates in 24+ countries across North America and Europe, serves thousands of clinics and millions of patients, and is led by CEO Mike Alvarez following a $100 million Series F financing in October 2024.

Short descriptiontext

Glooko operates a cloud-based diabetes data management platform that integrates 200+ devices and major EHR systems for hospitals, clinics, and people with diabetes, and provides FDA-cleared inpatient insulin dosing through the EndoTool system acquired from Monarch Medical Technologies in 2025.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
diabetes management software, remote patient monitoring, EHR integration platform, glycemic management system, digital health platform
Industry2 codes
PRIMARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLALAGAD
Endocrinology & Diabetes Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SIC code2 codes
  • Services-Offices & Clinics Of Doctors Of Medicine8011
  • Services-Misc Health & Allied Services, Nec8090
Product category
Digital Health Diabetes Management Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Enterprise Software Subscriptions
TypeSubscription Recurring
Description

Recurring SaaS revenue from hospitals, health systems, and clinics subscribing to the Glooko diabetes management platform. The company targets enterprise-level contracts with integrated delivery networks, positioning platform stickiness as a driver of recurring revenue streams.

tipranks.com
2Mobile App (Consumer)
TypeFreemium
Description

Free Glooko Mobile App for people with diabetes drives user acquisition and ecosystem lock-in. The app syncs data from over 200 devices and enables remote collaboration with care teams.

glooko.com
3EndoTool Inpatient Solutions
TypeSubscription Recurring
Description

Revenue from EndoTool Glucose Management System for hospital inpatient glycemic management, following acquisition of Monarch Medical Technologies in September 2025. FDA-cleared cloud-based insulin dosing platform for scalable hospital deployment.

businesswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details2 tiers
1Glooko Mobile App - Free for individuals with diabetes
ModelFreemiumBilling cadenceMonthly
Notes

Free mobile app for people with diabetes with core tracking and data synchronization features

glooko.com
2Enterprise healthcare provider platform - Custom pricing
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing for hospitals, health systems, and clinics. Platform subscription includes EHR integrations, device connectivity, and population health analytics.

tipranks.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1EndoTool
Description

FDA-cleared patient-specific insulin dosing platform for inpatient glycemic management in hospital settings; developed by Monarch Medical Technologies, a Glooko company.

glooko.com
+2 more records
Core offering1 text field

Glooko provides a cloud-based diabetes management platform that aggregates data from over 200 diabetes and health monitoring devices, integrates directly with major EHR systems, and delivers AI-powered glycemic insights to healthcare providers and patients. Its portfolio spans the outpatient Glooko Diabetes Management Platform, the free Glooko Mobile App for patients, and the EndoTool Glucose Management System (acquired from Monarch Medical Technologies) for inpatient insulin dosing, offering an end-to-end hospital-to-home diabetes care solution.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Reduction in HbA1c levels within 3 months of Glooko use, with sustained results after one year
+4 more records
Product overview1 text field

Glooko is a digital health company offering a connected care platform for diabetes management across the full care continuum. The portfolio consists of the outpatient Glooko Diabetes Management Platform and Glooko Web Application, the free Glooko Mobile App for people with diabetes, the inpatient EndoTool Glucose Management System (acquired from Monarch Medical Technologies in September 2025) with its cloud-based variant EndoTool IV Cloud, Glooko XT remote patient monitoring (France only), and the Glooko Transmitter hardware device. The platform aggregates patient data from more than 200 diabetes and health monitoring devices, integrates with major EHR systems, and delivers AI-powered insights for glycemic management in both outpatient and inpatient settings.

Product and service7 records
1Glooko Diabetes Management Platform
2Glooko Mobile App
CategoryConsumer Diabetes Mobile Application
Description

Free mobile app for people with diabetes that syncs and displays data from more than 200 devices including glucose monitors, insulin pumps, fitness trackers, and food tracking apps in one place. Provides easy-to-understand visualizations and secure sharing so users can monitor trends and remotely collaborate with their care team between appointments.

3EndoTool Glucose Management System
CategoryInpatient Glycemic Management Software
Description

FDA-cleared software using patented patient-specific algorithms for real-time insulin dosing in hospitalized patients. Originally developed by Monarch Medical Technologies and now part of Glooko, EndoTool is the only patient-specific insulin dosing system designed for inpatient glycemic management.

4EndoTool IV Cloud
CategoryInpatient Cloud Insulin Dosing Software
Description

First FDA-cleared cloud-based patient-specific insulin dosing platform for intravenous insulin therapy in hospital settings. Retains the core EndoTool IV dosing algorithm while adding cloud-based functionality for more scalable deployment, centralized updates, and reduced on-premises infrastructure requirements.

5Glooko XT
CategoryRemote Patient Monitoring Software (France)
Description

Remote patient monitoring platform for diabetes available exclusively in France, recognized by the French digital health agency as a certified digital medical device. Eligible for reimbursement for remote diabetes monitoring by the French National Health Insurance.

6Glooko Web Application
CategoryClinical Diabetes Web Application
Description

Diabetes management web platform used in-clinic or remotely by healthcare professionals and patients. Allows viewing of patient data from compatible medical devices and other health monitoring devices and enables healthcare professionals to support treatment of diabetes through analysis and monitoring of therapy and care programs.

7Glooko Transmitter
CategoryDiabetes Data Transmission Hardware
Description

Hardware device indicated for use by healthcare professionals in health care facilities to transfer predefined data from home monitoring devices to a server database, enabling instant and secure data upload during consultations.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1MyLife Diabetes Care
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-12
Description

Expanded partnership under which Glooko serves as MyLife Diabetes Care's primary data management platform for connected diabetes products. Builds on existing collaboration to support automated insulin delivery solutions and improve data accessibility for patients and healthcare teams. Partnership responds to growing adoption of connected therapy models in diabetes care. MyLife plans to strengthen its digital ecosystem using Glooko's management platform, including EndoTool for inpatient insulin dosing.

drugdeliverybusiness.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-08
Description

Integration partnership enabling Glooko platform to connect with Roche's Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution across 12 European countries. This is reportedly the first external platform connection to Roche's Accu-Chek SmartGuide CGM. Enables patients to consolidate CGM data alongside other health and medication data in a single view. Rollout in key European markets subject to local regulatory requirements.

Strategic tierCoreTypeOthersAnnounced on2025-09-23
Description

Acquisition of Monarch Medical Technologies, developer of EndoTool Glucose Management System. Expands Glooko's connected diabetes care platform into hospitals, strengthening inpatient glycemic management capabilities. EndoTool is FDA-cleared software using patented patient-specific algorithms for real-time insulin dosing in hospitalized patients. Glooko plans to integrate both offerings on single platform for comprehensive hospital-to-home diabetes management.

Strategic tierCoreTypeTechnology or Integration
Description

Strategic CGM integration expanding EMEA connectivity for Glooko's diabetes management platform

5Abbott Laboratories
Strategic tierCoreTypeTechnology or Integration
Description

Integration of Abbott's FreeStyle Libre continuous glucose monitoring (CGM) system into Glooko's platform in the United States. Allows patients to consolidate CGM data with insulin usage, exercise, diet, and other health metrics into unified view. Healthcare providers gain complete picture for clinical decision-making. Partnership covers individuals with Type 1 and Type 2 diabetes across U.S. healthcare systems.

drugdeliverybusiness.com
Strategic tierCoreTypeTechnology or Integration
Description

Platform integration allowing users to connect and sync data from Dexcom CGM devices with various diabetes management devices, enabling remote collaboration with healthcare providers

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint launch of personalized bolus insulin dosing support solution. Partnership combines Hedia's bolus calculator technology with Glooko's diabetes management platform to enhance outcomes for people on multiple daily insulin (MDI) therapy with precise dose recommendations

Strategic tierSecondaryTypeTechnology or Integration
Description

Partnership to revolutionize injectable therapy management with digital companion apps. Integration enables connectivity for injectable therapy management within Glooko's platform

Strategic tierSecondaryTypeTechnology or Integration
Description

Device manufacturer partner with insulin pump and delivery systems integrated with Glooko platform

Strategic tierCoreTypeTechnology or Integration
Description

Device manufacturer partner with insulin pump integration enabling data synchronization with Glooko platform

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Pharmaceutical partner for diabetes management solutions and potential therapeutic integrations

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Pharmaceutical partner for diabetes management solutions and therapeutic integrations

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Non-profit partner advancing Type 1 diabetes research and awareness

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Non-profit partner focused on improving Type 1 diabetes care through data and research

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Roche-owned diabetes self-management app and data platform tightly integrated with Accu-Chek meters. Directly comparable to Glooko's consumer-facing mobile app and outpatient platform; competes for the same endocrinologist and patient mindshare.

TypeDirect peer
Description

Leading CGM manufacturer with its own diabetes data platforms (Dexcom Clarity, Stelo). Although also a Glooko integration partner, Dexcom competes on the data analytics layer for CGM users and has incentive to consolidate the stack.

TypeBroad incumbent
Description

FreeStyle Libre CGM manufacturer with the LibreView and LibreLinkUp data platforms. Serves as both an integration partner to Glooko and a competitor offering device-tied diabetes data visualization for clinicians and patients.

TypeDirect peer
Description

Provider of the Glucommander inpatient insulin dosing software, the most direct competitor to Glooko's EndoTool IV Cloud in the hospital glycemic management space. Targets the same IDN and hospital pharmacy customers.

TypeDirect peer
Description

Digital therapeutics platform combining a smart glucose meter, mobile app, and AI-driven coaching for diabetes and other chronic conditions. Competes directly with Glooko's consumer-facing mobile experience and B2B2C employer/payer channel.

TypeEmerging player
Description

Alphabet life sciences subsidiary with Onduo, a virtual diabetes management program combining CGM, coaching, and clinician support. Competes for enterprise payer and provider contracts in digital diabetes management.

TypeBroad incumbent
Description

Insulin pump manufacturer with the t:connect diabetes management application. While a Glooko integration partner, Tandem also offers device-tied diabetes data visualization to endocrinologists, overlapping with Glooko's provider workflow.

TypeBroad incumbent
Description

Major insulin pump and CGM manufacturer with the CareLink diabetes management platform. Both a Glooko investor and integration partner, and a competitor offering its own end-to-end diabetes data platform to clinicians.

TypeDirect peer
Description

Consumer-facing diabetes management app and B2B platform offering glucose prediction, coaching, and connected device support. Directly comparable to Glooko Mobile in features and to Glooko's enterprise contracts in target customers.

TypeDirect peer
Description

Blood glucose monitoring company (OneTouch) with a connected diabetes management platform. Competes with Glooko in aggregating and visualizing BGM data for patients and providers, particularly in retail pharmacy and self-pay channels.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration13 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Glooko

Digital Health Diabetes Management Softwareglooko.com

Glooko operates a cloud-based diabetes data management platform that integrates 200+ devices and major EHR systems for hospitals, clinics, and people with diabetes, and provides FDA-cleared inpatient insulin dosing through the EndoTool system acquired from Monarch Medical Technologies in 2025.

What Glooko does

Glooko is a Palo Alto-based digital health company that operates a cloud-based diabetes data management platform serving healthcare providers, hospitals, health systems, and people with diabetes. The platform aggregates data from more than 200 diabetes and health monitoring devices, integrates with major EHR systems including Epic, Oracle Health, and MEDITECH, and processes over 3 billion data points per month, enabling population health analytics, remote patient monitoring, and clinical decision support across the care continuum.

The product portfolio spans the outpatient Glooko Diabetes Management Platform and Glooko Web Application, a free consumer-facing Glooko Mobile App, the France-only Glooko XT remote patient monitoring product (reimbursed by the French National Health Insurance), and the inpatient EndoTool Glucose Management System acquired from Monarch Medical Technologies in September 2025. EndoTool, an FDA-cleared patient-specific insulin dosing platform using patented algorithms, was extended with the FDA 510(k)-cleared EndoTool IV Cloud in May 2026, the first FDA-cleared cloud-based insulin dosing platform for IV therapy in hospital settings. Glooko also operates a life sciences vertical supplying real-world device data and clinical research support to pharmaceutical partners including Eli Lilly, Novo Nordisk, and Sanofi.

The business model combines enterprise SaaS subscriptions to hospitals, health systems, and clinics (quote-based annual contracts) with a freemium consumer mobile app, supplemented by EndoTool inpatient software revenue and life sciences partnerships. The company sells through direct enterprise field sales, mobile app stores, and device manufacturer channel partnerships, and holds multiple top-tier security and medical device certifications (HITRUST r2, ISO 27001, SOC 2 Type II, HIPAA, GDPR, ISO 13485, EU MDR Class IIa, FDA 21 CFR Part 11). As of 2026, Glooko operates in 24+ countries across North America and Europe, serves thousands of clinics and millions of patients, and is led by CEO Mike Alvarez following a $100 million Series F financing in October 2024.

Glooko firmographics

Firmographics
Name
Glooko
Legal name
Glooko, Inc.
Website
https://glooko.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Short description
Glooko operates a cloud-based diabetes data management platform that integrates 200+ devices and major EHR systems for hospitals, clinics, and people with diabetes, and provides FDA-cleared inpatient insulin dosing through the EndoTool system acquired from Monarch Medical Technologies in 2025.
Ownership category
akta.pro rank

Glooko industry classification

Industry
Product category
Digital Health Diabetes Management Software
SIC
Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLALAGAD
Endocrinology & Diabetes Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Diabetes management software
  • Remote patient monitoring
  • EHR integration platform
  • Glycemic management system
  • Digital health platform

Where Glooko is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Glooko business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Enterprise Software Subscriptions: Recurring SaaS revenue from hospitals, health systems, and clinics subscribing to the Glooko diabetes management platform. The company targets enterprise-level contracts with integrated delivery networks, positioning platform stickiness as a driver of recurring revenue streams.
  2. Mobile App (Consumer): Free Glooko Mobile App for people with diabetes drives user acquisition and ecosystem lock-in. The app syncs data from over 200 devices and enables remote collaboration with care teams.
  3. EndoTool Inpatient Solutions: Revenue from EndoTool Glucose Management System for hospital inpatient glycemic management, following acquisition of Monarch Medical Technologies in September 2025. FDA-cleared cloud-based insulin dosing platform for scalable hospital deployment.

Pricing tiers

ModelBillingPrice
FreemiumMonthlyGlooko Mobile App - Free for individuals with diabetes
SubscriptionAnnualEnterprise healthcare provider platform - Custom pricing

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Glooko product offering

Product offering

Core offering

Glooko provides a cloud-based diabetes management platform that aggregates data from over 200 diabetes and health monitoring devices, integrates directly with major EHR systems, and delivers AI-powered glycemic insights to healthcare providers and patients. Its portfolio spans the outpatient Glooko Diabetes Management Platform, the free Glooko Mobile App for patients, and the EndoTool Glucose Management System (acquired from Monarch Medical Technologies) for inpatient insulin dosing, offering an end-to-end hospital-to-home diabetes care solution.

Product overview

Glooko is a digital health company offering a connected care platform for diabetes management across the full care continuum. The portfolio consists of the outpatient Glooko Diabetes Management Platform and Glooko Web Application, the free Glooko Mobile App for people with diabetes, the inpatient EndoTool Glucose Management System (acquired from Monarch Medical Technologies in September 2025) with its cloud-based variant EndoTool IV Cloud, Glooko XT remote patient monitoring (France only), and the Glooko Transmitter hardware device. The platform aggregates patient data from more than 200 diabetes and health monitoring devices, integrates with major EHR systems, and delivers AI-powered insights for glycemic management in both outpatient and inpatient settings.

Differentiator

Problem solved

Functional benefit

Brands

  • EndoTool: FDA-cleared patient-specific insulin dosing platform for inpatient glycemic management in hospital settings; developed by Monarch Medical Technologies, a Glooko company.
  • Glooko XT
  • Glooko Mobile App

Products and services

  • Glooko Diabetes Management Platform
  • Glooko Mobile App Free mobile app for people with diabetes that syncs and displays data from more than 200 devices including glucose monitors, insulin pumps, fitness trackers, and food tracking apps in one place. Provides easy-to-understand visualizations and secure sharing so users can monitor trends and remotely collaborate with their care team between appointments.
  • EndoTool Glucose Management System FDA-cleared software using patented patient-specific algorithms for real-time insulin dosing in hospitalized patients. Originally developed by Monarch Medical Technologies and now part of Glooko, EndoTool is the only patient-specific insulin dosing system designed for inpatient glycemic management.
  • EndoTool IV Cloud First FDA-cleared cloud-based patient-specific insulin dosing platform for intravenous insulin therapy in hospital settings. Retains the core EndoTool IV dosing algorithm while adding cloud-based functionality for more scalable deployment, centralized updates, and reduced on-premises infrastructure requirements.
  • Glooko XT Remote patient monitoring platform for diabetes available exclusively in France, recognized by the French digital health agency as a certified digital medical device. Eligible for reimbursement for remote diabetes monitoring by the French National Health Insurance.
  • Glooko Web Application Diabetes management web platform used in-clinic or remotely by healthcare professionals and patients. Allows viewing of patient data from compatible medical devices and other health monitoring devices and enables healthcare professionals to support treatment of diabetes through analysis and monitoring of therapy and care programs.
  • Glooko Transmitter Hardware device indicated for use by healthcare professionals in health care facilities to transfer predefined data from home monitoring devices to a server database, enabling instant and secure data upload during consultations.

Quantifiable outcome

  • Reduction in HbA1c levels within 3 months of Glooko use, with sustained results after one year
  • +4 more outcomes

Companies that use Glooko

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Glooko technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration13 records

AI capability3 records

Feature4 records

Glooko partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core, secondary and minor.

  • MyLife Diabetes CarecoreStrategic or Co-development Partner · 12 May 2026Expanded partnership under which Glooko serves as MyLife Diabetes Care's primary data management platform for connected diabetes products. Builds on existing collaboration to support automated insulin delivery solutions and improve data accessibility for patients and healthcare teams. Partnership responds to growing adoption of connected therapy models in diabetes care. MyLife plans to strengthen its digital ecosystem using Glooko's management platform, including EndoTool for inpatient insulin dosing.
  • Roche Diabetes CarecoreTechnology or Integration · 8 March 2026Integration partnership enabling Glooko platform to connect with Roche's Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution across 12 European countries. This is reportedly the first external platform connection to Roche's Accu-Chek SmartGuide CGM. Enables patients to consolidate CGM data alongside other health and medication data in a single view. Rollout in key European markets subject to local regulatory requirements.
  • Monarch Medical TechnologiescoreOthers · 23 September 2025Acquisition of Monarch Medical Technologies, developer of EndoTool Glucose Management System. Expands Glooko's connected diabetes care platform into hospitals, strengthening inpatient glycemic management capabilities. EndoTool is FDA-cleared software using patented patient-specific algorithms for real-time insulin dosing in hospitalized patients. Glooko plans to integrate both offerings on single platform for comprehensive hospital-to-home diabetes management.
  • Roche Diabetes CarecoreTechnology or IntegrationStrategic CGM integration expanding EMEA connectivity for Glooko's diabetes management platform
  • Abbott LaboratoriescoreTechnology or IntegrationIntegration of Abbott's FreeStyle Libre continuous glucose monitoring (CGM) system into Glooko's platform in the United States. Allows patients to consolidate CGM data with insulin usage, exercise, diet, and other health metrics into unified view. Healthcare providers gain complete picture for clinical decision-making. Partnership covers individuals with Type 1 and Type 2 diabetes across U.S. healthcare systems.
  • DexcomcoreTechnology or IntegrationPlatform integration allowing users to connect and sync data from Dexcom CGM devices with various diabetes management devices, enabling remote collaboration with healthcare providers
  • HediacoreStrategic or Co-development PartnerJoint launch of personalized bolus insulin dosing support solution. Partnership combines Hedia's bolus calculator technology with Glooko's diabetes management platform to enhance outcomes for people on multiple daily insulin (MDI) therapy with precise dose recommendations
  • Innovation ZedsecondaryTechnology or IntegrationPartnership to revolutionize injectable therapy management with digital companion apps. Integration enables connectivity for injectable therapy management within Glooko's platform
  • YpsomedsecondaryTechnology or IntegrationDevice manufacturer partner with insulin pump and delivery systems integrated with Glooko platform
  • Tandem Diabetes CarecoreTechnology or IntegrationDevice manufacturer partner with insulin pump integration enabling data synchronization with Glooko platform
  • Eli LillysecondaryStrategic or Co-development PartnerPharmaceutical partner for diabetes management solutions and potential therapeutic integrations
  • SanofisecondaryStrategic or Co-development PartnerPharmaceutical partner for diabetes management solutions and therapeutic integrations
  • JDRF ( Breakthrough T1D)minorStrategic or Co-development PartnerNon-profit partner advancing Type 1 diabetes research and awareness
  • T1D ExchangeminorStrategic or Co-development PartnerNon-profit partner focused on improving Type 1 diabetes care through data and research

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Glooko competitors and assessment

Company assessment

Direct peers

  • mySugr (Roche Diabetes Care): Roche-owned diabetes self-management app and data platform tightly integrated with Accu-Chek meters. Directly comparable to Glooko's consumer-facing mobile app and outpatient platform; competes for the same endocrinologist and patient mindshare.
  • Dexcom: Leading CGM manufacturer with its own diabetes data platforms (Dexcom Clarity, Stelo). Although also a Glooko integration partner, Dexcom competes on the data analytics layer for CGM users and has incentive to consolidate the stack.
  • Glytec: Provider of the Glucommander inpatient insulin dosing software, the most direct competitor to Glooko's EndoTool IV Cloud in the hospital glycemic management space. Targets the same IDN and hospital pharmacy customers.
  • DarioHealth: Digital therapeutics platform combining a smart glucose meter, mobile app, and AI-driven coaching for diabetes and other chronic conditions. Competes directly with Glooko's consumer-facing mobile experience and B2B2C employer/payer channel.
  • One Drop: Consumer-facing diabetes management app and B2B platform offering glucose prediction, coaching, and connected device support. Directly comparable to Glooko Mobile in features and to Glooko's enterprise contracts in target customers.
  • LifeScan: Blood glucose monitoring company (OneTouch) with a connected diabetes management platform. Competes with Glooko in aggregating and visualizing BGM data for patients and providers, particularly in retail pharmacy and self-pay channels.

Broad incumbents

  • Abbott Diabetes Care: FreeStyle Libre CGM manufacturer with the LibreView and LibreLinkUp data platforms. Serves as both an integration partner to Glooko and a competitor offering device-tied diabetes data visualization for clinicians and patients.
  • Tandem Diabetes Care: Insulin pump manufacturer with the t:connect diabetes management application. While a Glooko integration partner, Tandem also offers device-tied diabetes data visualization to endocrinologists, overlapping with Glooko's provider workflow.
  • Medtronic Diabetes: Major insulin pump and CGM manufacturer with the CareLink diabetes management platform. Both a Glooko investor and integration partner, and a competitor offering its own end-to-end diabetes data platform to clinicians.

Emerging players

  • Verily (Onduo): Alphabet life sciences subsidiary with Onduo, a virtual diabetes management program combining CGM, coaching, and clinician support. Competes for enterprise payer and provider contracts in digital diabetes management.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Glooko social profiles

Digital presence

Glooko compliance and trust

Trust signal

Compliance12 records

Glooko financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Glooko leadership team

Management profile

Number of profiles

Profiles16 records

Glooko subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Glooko funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Glooko M&A and investment

M&A and investment

M&A4 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Glooko

What does Glooko do?

Glooko provides a cloud-based diabetes management platform that aggregates data from over 200 diabetes and health monitoring devices, integrates directly with major EHR systems, and delivers AI-powered glycemic insights to healthcare providers and patients. Its portfolio spans the outpatient Glooko Diabetes Management Platform, the free Glooko Mobile App for patients, and the EndoTool Glucose Management System (acquired from Monarch Medical Technologies) for inpatient insulin dosing, offering an end-to-end hospital-to-home diabetes care solution.

Is Glooko a public or private company?

Glooko is a private company. It is classified as venture growth investor backed and is currently operating.

When was Glooko founded?

Glooko was founded in 2012. It employs 101 to 250 people.

Where is Glooko based?

Glooko is headquartered in Palo Alto, United States, in the North America region.

How does Glooko make money?

Three revenue lines are on record. Enterprise Software Subscriptions are the primary driver. The others are mobile App (Consumer) and endoTool Inpatient Solutions.

Who are Glooko's main competitors?

Direct peers on record are mySugr (Roche Diabetes Care), Dexcom, Glytec, DarioHealth, One Drop and LifeScan. Broad incumbents are Abbott Diabetes Care, Tandem Diabetes Care and Medtronic Diabetes. Verily (Onduo) is listed as an emerging player.

Does Glooko have an API?

Yes. Glooko offers an API and EHR Integration Portal available at developers.glooko.com. The portal provides API Terms of Service for developers. Specific technical details such as API type (REST, GraphQL, webhooks), authentication method, rate limits, versioning, or sandbox availability are not stated in the available source materials. Developer documentation is at developers.glooko.com.

What industry is Glooko in?

Glooko's product category is Digital Health Diabetes Management Software. Its primary akta.pro industry code is HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators), with a secondary code of HLALAGAD, Endocrinology & Diabetes Telemedicine Platforms. Its SIC code is 8011.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogGlooko Launches Glooko EndoTool IV Cloud, Advancing Patient-Specific Glycemic Management for HospitalsGlooko launched Glooko EndoTool IV Cloud, an FDA-cleared SaaS-based inpatient IV insulin dosing solution. The platform uses patient-specific data to recommend dosing adjustments, with 2025 customer data showing an average severe hypoglycemia rate below 40 mg/dL of 0.006%. The product is now commercially available in the United States.HIT ConsultantGlooko Launches EndoTool IV Cloud: Patient-Specific Glycemic Management for HospitalsGlooko launched EndoTool IV Cloud in the US, a cloud-based IV insulin decision support platform. Clinical validation showed a severe hypoglycemia rate of 0.0013% in patients with severely impaired renal function. The platform uses adaptive modeling to update dosing recommendations based on real-time patient data.DigitalhealthwireEasing the Data Burden in Diabetes CareGlooko's 2025 Annual Diabetes Report details over 60 billion CGM readings from 1 million patients and 30,500 clinicians. Its overnight hypoglycemia model identified high-risk patients with a 2.79x lift in observed events across 586,549 patient weeks. The report advocates shifting from retrospective review to prioritized action.DrugdeliverybusinessGlooko launches EHR integration for insulin pumpsGlooko announced the launch of its Insulin Pump Settings Electronic Health Record integration capability, a first-of-its-kind feature that visualizes critical insulin pump configuration data directly into clinical workflows. The integration eliminates the need for clinicians to manually transcribe up to 24 different data points by pulling structured pump settings data into EHR flowsheets. The company says the offering creates a device-agnostic diabetes layer for EHRs and establishes a structured data foundation for more advanced clinical decision support in the future.Mpo-magGlooko Rolls Out Insulin Pump Settings EHR IntegrationGlooko launched an EHR integration that visualizes insulin pump settings into clinical workflows, replacing manual transcription of up to 24 data points. The device-agnostic layer normalizes pump data across manufacturers, and the company recently received FDA 510(k) clearance for its EndoTool IV Cloud.TipranksGlooko – Weekly RecapGlooko, a digital health company specializing in diabetes management, highlighted its recent efforts to expand clinical and hospital partnerships, with a focus on interoperability and enterprise solutions. The company emphasized its integration with hospitals, electronic health records, and clinical workflows to strengthen its market position and recurring revenue streams.BastillepostGlooko Announces FDA 510(k) Clearance for EndoTool IV CloudGlooko, Inc. announced on May 14, 2026 that the U.S. Food and Drug Administration has granted 510(k) clearance for EndoTool IV Cloud, the first FDA-cleared cloud-based patient-specific insulin dosing platform for intravenous insulin therapy in hospital settings. The clearance, which follows Glooko's acquisition of Monarch Medical Technologies in September 2025, enables the company to transition its existing EndoTool IV solution to a more scalable cloud-based architecture with streamlined deployment and maintenance. Glooko expects to launch EndoTool IV Cloud commercially in the U.S. before the end of the year.